World Journal of Pharmacology and Toxicology
Open Access

Tropical diseases; global public health; healthcare infrastructure; technological innovation; collaborative research initiatives; potential efficacy

Introduction

Tropical diseases, often referred to as Neglected Tropical Diseases (NTDs), represent a group of infectious diseases that disproportionately affect populations in tropical and subtropical regions, particularly those with limited access to healthcare resources and infrastructure. These diseases, which include malaria, dengue fever, leishmaniasis, Chagas disease, and others, contribute significantly to the global burden of illness, morbidity, and mortality, posing significant challenges to public health systems worldwide. The development of safe, effective, and affordable drugs for the prevention and treatment of tropical diseases is essential for reducing their impact and improving the health outcomes of affected populations. In recent years, there have been notable advancements in drug discovery for tropical diseases, driven by scientific innovation, technological breakthroughs, and collaborative research efforts across disciplines and sectors. This introduction provides an overview of the current landscape of drug discovery for tropical diseases, highlighting key advancements, challenges, and opportunities in this critical field of global health. Advancements in drug discovery for tropical diseases have been facilitated by a deeper understanding of the molecular mechanisms underlying pathogen biology and disease pathogenesis. Target-based drug discovery approaches, which aim to identify specific molecular targets within pathogens, have enabled the development of novel drug candidates with potential efficacy against a range of tropical diseases [1, 2].

Description

Advancements in drug discovery for tropical diseases represent a critical frontier in global health research, aiming to address the substantial burden of infectious diseases that disproportionately affect populations in tropical and subtropical regions. These diseases, often neglected and endemic in low-resource settings, pose significant challenges to public health systems and socioeconomic development. Recent years have witnessed remarkable progress in drug discovery efforts targeting tropical diseases, driven by a convergence of scientific innovation, technological advancements, and collaborative initiatives. Key advancements include:

Target-based drug discovery

Researchers are increasingly focusing on identifying specific molecular targets within pathogens responsible for tropical diseases. This approach enables the development of more selective and efficacious drugs while minimizing off-target effects. For example, identifying essential enzymes or proteins in the life cycle of malaria parasites has led to the discovery of new antimalarial agents [3].

High-Throughput Screening (HTS) technologies

HTS platforms allow researchers to rapidly screen large libraries of compounds for potential activity against tropical disease pathogens. Coupled with advances in robotics, automation, and assay development, HTS has accelerated the identification of lead compounds with therapeutic potential [4, 5].

Computational modeling and virtual screening

Computational techniques, such as molecular docking and dynamics simulations, facilitate the rational design and optimization of drug candidates. Virtual screening approaches allow researchers to screen large chemical databases to identify molecules likely to interact with target proteins, expediting the drug discovery process [6].

Phenotypic screening

Phenotypic screening involves testing candidate compounds against whole organisms or cells to assess their biological activity. This approach is particularly valuable for identifying compounds with novel mechanisms of action and addressing complex, multifactorial diseases such as leishmaniasis and Chagas disease [7].

Drug repurposing

Repurposing existing drugs approved for other indications offers a cost-effective and expedited approach to drug discovery for tropical diseases. Compounds originally developed for unrelated conditions may exhibit activity against tropical disease pathogens, providing new treatment options with known safety profiles [8].

Drug resistance

The emergence and spread of drug-resistant strains of tropical disease pathogens pose a significant threat to treatment efficacy [9].

Limited financial incentives

The low commercial viability of drugs for neglected tropical diseases often deters pharmaceutical companies from investing in research and development.

Regulatory barriers

Obtaining regulatory approval for new drugs, particularly for diseases endemic in resource-limited settings, can be challenging due to stringent regulatory requirements and limited infrastructure for conducting clinical trials. Addressing these challenges requires sustained investment in research, collaboration between stakeholders, and innovative approaches to drug discovery and development. By leveraging advancements in science and technology, as well as fostering partnerships between academia, industry, governments, and non-profit organizations, the global community can accelerate progress towards the development of safe, effective, and accessible drugs for tropical diseases, ultimately improving the health and well-being of millions of people worldwide [10].

Conclusion

In conclusion, the advancements in drug discovery for tropical diseases represent a beacon of hope in the fight against these debilitating illnesses that disproportionately affect vulnerable populations in tropical and subtropical regions. The convergence of scientific innovation, technological progress, and collaborative efforts has yielded promising developments in identifying new drug targets, screening methodologies, and repurposing existing drugs for neglected tropical diseases. Despite significant progress, challenges such as drug resistance, limited financial incentives, and regulatory barriers persist, underscoring the need for sustained commitment and investment from stakeholders across sectors. Overcoming these challenges will require continued collaboration between academia, industry, governments, non-profit organizations, and affected communities to drive forward research, development, and access to effective treatments.

1. Lammerhofer M, Weckwerth W (2013) Metabolomics in practice: successful strategies to generate and analyze metabolic data. Weinheim: Wiley-VCH Verlag.

Google Scholar

2. Haycock JW (2011) 3D cell culture: a review of current approaches and techniques. Methods Mol Biol 695:1-15.

Indexed at, Crossref, Google Scholar

3. Fatehullah A, Tan SH, Barker N (2016) Organoids as an in vitro model of human development and disease. Nat Cell Biol. 18: 246-254.

Indexed at, Crossref, Google Scholar

4. Jeong ES, Kim G, Shin HJ (2015) Increased serum bile acid concentration following low-dose chronic administration of thioacetamide in rats, as evidenced by metabolomic analysis. Toxicol Appl Pharmacol. 288: 213-222.

Indexed at, Crossref, Google Scholar

5. Mattes W, Davis K, Fabian E (2014) Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma. Toxicol Lett. 230: 467-478.

Indexed at, Crossref, Google Scholar

6. Weiler S, Merz M, Kullak-Ublick GA (2015) Drug-induced liver injury: the dawn of biomarkers? F1000Prime Rep. 7: 34.

Indexed at, Crossref, Google Scholar

7. Zaitsu K, Hayashi Y, Kusano M (2016) Application of metabolomics to toxicology of drugs of abuse: a mini review of metabolomics approach to acute and chronic toxicity studies. Drug Metab Pharmacokinet. 31:21-26.

Indexed at, Crossref, Google Scholar

8. Forgue P, Halouska S, Werth M (2006) NMR metabolic profiling of Aspergillus nidulans to monitor drug and protein activity. J Proteome Res 5:1916-1923.

Indexed at, Crossref, Google Scholar

9. Lefort N, Brown A, Lloyd V (2014) ¹H NMR metabolomics analysis of the effect of dichloroacetate and allopurinol on breast cancers. J Pharm Biomed Anal 93:77-85.

Indexed at, Crossref, Google Scholar

10. Yoshinari K, Yamashita K (2016) Analytical chemistry for ADMET research: recent advances and future directions in LC–MS/MS and omics approaches. Drug Metab Pharmacokinet 31:1-2.

Indexed at, Crossref, Google Scholar